James Brumley
James Brumley (RSS)
InvestorPlace Contributor

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He's now primarily a freelance writer, tapping more than a decade's worth of broad experience to help investors get more out of the market.

Read complete bio
Recent Articles

3 Healthcare Acquisitions Google Should Consider

Sep. 12, 2014, 2:40 pm EDT – The best way for Google to make an even bigger splash in healthcare is through smart acquisitions like these 3 companies. More 

5 Value Stocks to Buy Now

Sep. 9, 2014, 9:50 am EDT – Investors looking for some new stocks to buy may want to consider these value stocks first. More 

Merck’s Keytruda Win Signals a Big Shift for Big Pharma

Sep. 8, 2014, 9:57 am EDT – MRK per-share profits and revenue are poised to rebound now that its research and development efforts are getting traction. More 

Best $5 Stocks to Buy Now

Sep. 4, 2014, 11:10 am EDT – Traders looking for new stocks to buy should start the search with stocks under $5 per share. Here are 5 of the best stocks in that price range. More 

Atlantic City Closings a Grave Omen for Casino Stocks

Sep. 3, 2014, 10:35 am EDT – Casino stocks have been hit-and-miss for a while, but recent abdications suggest we're entering a rough patch. More 

Investing in Drones: Impracticality Could Prevent Profits

Sep. 2, 2014, 11:15 am EDT – Drones may change the world ... but not anytime soon. In fact, some of the apparent "drone stocks" really qualify as drone stocks. More 

The Upcoming Apple Event is a Coin Toss for AAPL Stock

Aug. 29, 2014, 9:07 am EDT – The upcoming Apple event is likely to unveil the new iPhone or the Apple iWatch. Either way, betting on the stock's response is an ill-advised bet. More 

7 Shareholder Perks That Sweeten the Pot for Investors

Aug. 29, 2014, 6:00 am EDT – Shareholder perks offer a little something extra to those folks who've taken on extra risk of owning a stake in the company. Here are some of the best. More 

Will Pfizer Take One Last Swing at AstraZeneca?

Aug. 27, 2014, 11:45 am EDT – The Pfizer-AstraZeneca saga isn't over yet, but it probably will be soon enough ... with no changes to the status quo. More 

The Sectors to Watch Now That the S&P 500 Has Hurdled 2000

Aug. 26, 2014, 8:30 am EDT – The S&P 2000 discussion can graduate to the next stage now that the S&P 500 has reached the 2000 milestone. More